ORION CORP.B UNSP.ADR 1/2 (OFK0) - Total Assets
Based on the latest financial reports, ORION CORP.B UNSP.ADR 1/2 (OFK0) holds total assets worth €2.08 Billion EUR (≈ $2.43 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
ORION CORP.B UNSP.ADR 1/2 - Total Assets Trend (2022–2025)
This chart illustrates how ORION CORP.B UNSP.ADR 1/2's total assets have evolved over time, based on quarterly financial data. Also see OFK0 company net worth for the company's overall valuation and market capitalisation.
ORION CORP.B UNSP.ADR 1/2 - Asset Composition Analysis
Current Asset Composition (December 2025)
ORION CORP.B UNSP.ADR 1/2's total assets of €2.08 Billion consist of 66.9% current assets and 33.1% non-current assets. Review ORION CORP.B UNSP.ADR 1/2 (OFK0) financial obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 8.0% |
| Accounts Receivable | €352.30 Million | 17.5% |
| Inventory | €456.30 Million | 22.7% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €100.30 Million | 5.0% |
| Goodwill | €87.20 Million | 4.3% |
Asset Composition Trend (2022–2025)
This chart illustrates how ORION CORP.B UNSP.ADR 1/2's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See ORION CORP.B UNSP.ADR 1/2 stock quote for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ORION CORP.B UNSP.ADR 1/2's current assets represent 66.9% of total assets in 2025, an increase from 58.4% in 2022.
- Cash Position: Cash and equivalents constituted 8.0% of total assets in 2025, down from 22.1% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 8.0% of total assets, a decrease from 11.0% in 2022.
- Asset Diversification: The largest asset category is inventory at 22.7% of total assets.
ORION CORP.B UNSP.ADR 1/2 Competitors by Total Assets
Key competitors of ORION CORP.B UNSP.ADR 1/2 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Novartis AG
SW:NOVN
|
Switzerland | CHF118.89 Billion |
|
AstraZeneca PLC
LSE:AZN
|
UK | GBX116.43 Billion |
|
Pfizer Inc
SA:PFIZ34
|
Brazil | R$201.13 Billion |
|
AbbVie Inc
NYSE:ABBV
|
USA | $136.46 Billion |
|
Merck & Company Inc
NYSE:MRK
|
USA | $129.80 Billion |
|
AstraZeneca PLC
F:ZEGA
|
Germany | €114.46 Billion |
|
Pfizer Inc
NYSE:PFE
|
USA | $201.13 Billion |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952
|
China | CN¥2.29 Billion |
ORION CORP.B UNSP.ADR 1/2 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.77 | 3.90 | 2.42 |
| Quick Ratio | 1.13 | 2.34 | 1.41 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €612.50 Million | €806.40 Million | €571.90 Million |
ORION CORP.B UNSP.ADR 1/2 - Advanced Valuation Insights
This section examines the relationship between ORION CORP.B UNSP.ADR 1/2's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.63 |
| Latest Market Cap to Assets Ratio | 4.13 |
| Asset Growth Rate (YoY) | 23.4% |
| Total Assets | €2.01 Billion |
| Market Capitalization | $8.31 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values ORION CORP.B UNSP.ADR 1/2's assets at a significant premium (4.13x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: ORION CORP.B UNSP.ADR 1/2's assets grew by 23.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for ORION CORP.B UNSP.ADR 1/2 (2022–2025)
The table below shows the annual total assets of ORION CORP.B UNSP.ADR 1/2 from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €2.01 Billion ≈ $2.35 Billion |
+23.37% |
| 2024-12-31 | €1.63 Billion ≈ $1.90 Billion |
+13.24% |
| 2023-12-31 | €1.44 Billion ≈ $1.68 Billion |
-4.32% |
| 2022-12-31 | €1.50 Billion ≈ $1.76 Billion |
-- |
About ORION CORP.B UNSP.ADR 1/2
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflam… Read more